Nine months after multiple biosimilar rivals to Humira (adalimumab) launched in the US, the immediate shape of competition to the once top-selling immunology brand is clear. Biosimilars struggled to capture meaningful market share in 2023, together accounting for just 2% of the market by the end of the year (see sidebar).
However, Organon – one of the leading players in the US adalimumab market, with its Samsung Bioepis-partnered Hadlima (adalimumab-bwwd) version – had from the start predicted only a “modest ramp” in sales in 2023 ahead of a more significant contribution from Hadlima in 2024 and 2025
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?